Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 715-717

  Mroz, Edmund A ^a   Rocco, James W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

CANCER CHEMOTHERAPY; EDITORIAL; HEAD AND NECK CARCINOMA; HUMAN; MOUTH CANCER; MOUTH TUMOR; ORGAN PRESERVATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; GENETIC SCREENING; GENETICS; MORTALITY; MUTATION; NOTE; NUCLEOTIDE SEQUENCE; ORAL SURGERY; PATIENT SELECTION; PREDICTION AND FORECASTING; SQUAMOUS CELL CARCINOMA; TIME; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FLUOROURACIL; GENETIC TESTING; HUMANS; MOUTH NEOPLASMS; MUTATION; NEOADJUVANT THERAPY; ORAL SURGICAL PROCEDURES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77649211801     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3475     Document Type: Editorial

References (20)

1. Perrone F, Bossi P, Cortelazzi B, et al: TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 28:761-766, 2010
2. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 21:327-333, 2003 (Pubitemid 46606163)
3. Erber R, Conradt C, Homann N, et al: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679, 1998 (Pubitemid 28175048)
4. Poeta ML, Manola J, Goldwasser MA, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552-2561, 2007 (Pubitemid 350294222)
5. Cabelguenne A, Blons H, de Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18:1465-1473, 2000 (Pubitemid 30205392)
6. Temam S, Flahault A, Perie S, et al: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385-394, 2000 (Pubitemid 30056429)
7. Bergamaschi D, Gasco M, Hiller L, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402, 2003 (Pubitemid 38340307)
8. Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328-3337, 2004 (Pubitemid 38669822)
9. Kato S, Han SY, Liu W, et al: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100:8424-8429, 2003 (Pubitemid 36842561)
10. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007 (Pubitemid 46744292)
11. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
12. Partridge M, Costea DE, Huang X: The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 36:1123-1138, 2007
13. Rocco JW, Leong CO, Kuperwasser N, et al: P63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45-56, 2006
14. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633, 1996
15. Michaud WA, Nichols AC, Mroz EA, et al: Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15:1645-1654, 2009
16. Kumar B, Cordell KG, Lee JS, et al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008
17. Green DR, Kroemer G: Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127-1130, 2009
18. Forastiere AA, Trotti A, Pfister DG, et al: Head and neck cancer: Recent advances and new standards of care. J Clin Oncol 24:2603-2605, 2006
19. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008 (Pubitemid 351480538)
20. Gourin CG, Johnson JT: Indications for primary surgical care of patients with squamous cell carcinoma of the head and neck. Laryngoscope 10.1002/lary. 20619, 2009